Literature DB >> 7773801

Pentoxifylline improves survival and reduces tumor necrosis factor, interleukin-6, and endothelin-1 in fulminant intra-abdominal sepsis in rats.

R Lundblad1, P Ekstrøm, K E Giercksky.   

Abstract

The influence of pentoxifylline (PTX) on mortality and some important mediators was studied in a model of cecal perforation with fulminant intra-abdominal sepsis in rats. Cumulative mortality was registered in three groups of animals: untreated sepsis (n = 36), sepsis + PTX 20 mg/kg/24 h (n = 24), and sepsis + PTX 80 mg/kg/24 h (n = 24). PTX therapy was started at sepsis induction or after 4 h, and mortality was reduced from 89% in untreated sepsis to 60-66% in the PTX groups. Levels of sepsis mediators were studied in two groups: untreated sepsis and sepsis + PTX 40 mg/kg started 1 h after sepsis induction. In both groups 6-10 animals were sacrificed at 4 and 8 h to measure blood levels of bacteria, endotoxin, tumor necrosis factor (TNF), interleukin-6 (IL-6), endothelin-1, lactate, neutrophils, and packed cell volume. Cecal perforation gave high levels of bacteria, endotoxin, TNF, IL-6, and endothelin-1, leading to dehydration, lactacidosis, neutropenia, and death. Treatment with PTX did not modify dehydration, neutropenia, or concentrations of bacteria and endotoxin. Release of endothelin-1 was delayed, TNF burst was nearly abolished, and levels of IL-6 and lactate were substantially suppressed. In summary, PTX improves survival and reduces blood concentrations of TNF, IL-6, lactate, and endothelin-1 in fulminant intra-abdominal sepsis in rats. The primary effect of PTX in this sequence is probably reduction of TNF.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7773801     DOI: 10.1097/00024382-199503000-00009

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  10 in total

1.  Pentoxifylline does not improve outcome in a murine model for the multiple-organ dysfunction syndrome.

Authors:  T J H Volman; R J A Goris; T Hendriks
Journal:  Intensive Care Med       Date:  2005-02-15       Impact factor: 17.440

2.  Anti-inflammatory role in septic shock of pituitary adenylate cyclase-activating polypeptide receptor.

Authors:  Carmen Martinez; Catalina Abad; Mario Delgado; Alicia Arranz; Maria G Juarranz; Nieves Rodriguez-Henche; Philippe Brabet; Javier Leceta; Rosa P Gomariz
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-15       Impact factor: 11.205

3.  In vivo efficacy of trovafloxacin (CP-99,217), a new quinolone, in experimental intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli.

Authors:  H Thadepalli; U Reddy; S K Chuah; F Thadepalli; C Malilay; R J Polzer; N Hanna; A Esfandiari; P Brown; S Gollapudi
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

4.  Systemic inflammatory effects of traumatic brain injury, femur fracture, and shock: an experimental murine polytrauma model.

Authors:  C Probst; M J Mirzayan; P Mommsen; C Zeckey; T Tegeder; L Geerken; M Maegele; A Samii; M van Griensven
Journal:  Mediators Inflamm       Date:  2012-03-04       Impact factor: 4.711

5.  Pentoxifylline decreases allodynia and hyperalgesia in a rat model of neuropathic pain.

Authors:  A Vakili; Mj Shirvanian; Ha Safakhah; A Rashidy-Pour
Journal:  Daru       Date:  2011       Impact factor: 3.117

6.  Pentoxifylline immunomodulation in the treatment of experimental chronic pulmonary paracoccidioidomycosis.

Authors:  Damaris Elena Lopera; Tonny Williams Naranjo; José Miguel Hidalgo; Laura Echeverri; Jairo Hernando Patiño; Ángela Restrepo Moreno; Henrique Leonel Lenzi; Luz Elena Cano
Journal:  Fibrogenesis Tissue Repair       Date:  2015-06-01

7.  Yokukansan, a Kampo medicine, prevents the development of morphine tolerance through the inhibition of spinal glial cell activation in rats.

Authors:  Mariko Takemoto; Masataka Sunagawa; Mayumi Okada; Hideshi Ikemoto; Hiroki Suga; Ayami Katayama; Hiroshi Otake; Tadashi Hisamitsu
Journal:  Integr Med Res       Date:  2015-12-31

8.  The INIS Study. International Neonatal Immunotherapy Study: non-specific intravenous immunoglobulin therapy for suspected or proven neonatal sepsis: an international, placebo controlled, multicentre randomised trial.

Authors: 
Journal:  BMC Pregnancy Childbirth       Date:  2008-12-08       Impact factor: 3.007

9.  Expression profiling of genes modulated by minocycline in a rat model of neuropathic pain.

Authors:  Ewelina Rojewska; Michal Korostynski; Ryszard Przewlocki; Barbara Przewlocka; Joanna Mika
Journal:  Mol Pain       Date:  2014-07-19       Impact factor: 3.395

Review 10.  Botulinum Toxin Type A-A Modulator of Spinal Neuron-Glia Interactions under Neuropathic Pain Conditions.

Authors:  Ewelina Rojewska; Anna Piotrowska; Katarzyna Popiolek-Barczyk; Joanna Mika
Journal:  Toxins (Basel)       Date:  2018-04-02       Impact factor: 4.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.